

**PRESS RELEASE**

08 August 2023 08:30:00 CEST



## **Lipum in collaboration with the Karolinska Institute**

**Lipum (publ) has entered a collaboration with researchers at the Karolinska Institute (KI), Division of Rheumatology at the Department of Medicine in Sweden.**

Lipum's drug candidate SOL-116 has been developed for treatment of chronic inflammatory diseases and a clinical phase 1 safety study is currently ongoing. In parallel, preclinical studies on the target molecule bile salt-stimulated lipase (BSSL) and SOL-116 are also prioritised.

The intention of the research collaboration between Lipum and KI is to thoroughly explore the role of BSSL in the immune system in general and in rheumatoid arthritis in particular and to further elucidate the mode of action of the anti-BSSL antibody and drug candidate SOL-116.

*"We are very enthusiastic about the opportunity to collaborate with such a prominent research institution. The cooperation agreement is for two years, and I am confident that valuable knowledge will be added to our exploitation of SOL-116."*, says CEO Einar Pontén.

The Division of Rheumatology at KI conduct research on the etiology, molecular mechanisms, treatments, and outcome of many of the most severe chronic rheumatic inflammatory diseases. The research is translational spanning from molecular biology to clinical research.

*"The project is very important as there is a pronounced need for new drugs with alternative modes of action in the field of chronic inflammatory diseases."* says the project research leader Associate Professor Bence Réthi at KI.

### **Contacts**

Einar Pontén, CEO

E-post: [einar.ponten@lipum.se](mailto:einar.ponten@lipum.se)

Mobile: +46 70 578 34 95

Web: [www.lipum.se](http://www.lipum.se)

### **About Us**

Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum's unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

**PRESS RELEASE**

08 August 2023 08:30:00 CEST



**Attachments**

[Lipum in collaboration with the Karolinska Institute](#)